Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
- Japan to Participate in Global PIII Study of Forxiga for Type 1 Diabetes: AZ
August 25, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- Eli Lilly Files for Psoriasis Treatment Ixekizumab in Japan
August 24, 2015
- Janssen, National Center of Neurology and Psychiatry to Jointly Develop Biomarkers for AD Drug Reminyl
August 24, 2015
- EMA Accepts Application for Once-Weekly Oral Proteasome Inhibitor Ixazomib: Takeda
August 24, 2015
- Lilly Challenges Invalidation Ruling on Evista Usage Patent
August 21, 2015
- Astellas to Adopt One-Rep-for-One-Institution Regime in October
August 21, 2015
- Loxonin Suffers Most in Decrease in No. of Prescriptions Following Introduction of Generic Coefficient: Survey
August 21, 2015
- Announcement: 2015 Asia Pacific Meetings of ISMPP (Beijing on Aug. 30, Tokyo on Sept. 2)
August 20, 2015
- Anti-PD-L1 Antibody Atezolizumab Demonstrates Tumor Reduction Efficacy in NSCLC in PII Study: Roche
August 20, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…